血清 Sema7A 在急性主动脉夹层患者中升高。

Serum Sema7A is increased in patients with acute aortic dissection.

机构信息

Department of Clinical Laboratory Medicine, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

Department of Geriatrics, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

出版信息

Expert Rev Mol Diagn. 2023 Jul-Dec;23(11):1027-1035. doi: 10.1080/14737159.2023.2254693. Epub 2023 Sep 12.

DOI:10.1080/14737159.2023.2254693

PMID:37698489

Abstract

BACKGROUND

To observe the level of serum Sema7A in acute aortic dissection (AAD) and its diagnostic value for AAD.

RESEARCH DESIGN AND METHODS

Patients with sudden chest pain including AAD, acute myocardial infarction (AMI) or pulmonary embolism (PE) were enrolled. Patients without chest pain or cardiovascular diseases were included as the controls. Serum Sema7A and plasma D-dimer were detected and compared in each group.

RESULTS

85 AAD patients, 55 AMI patients, 15 PE patients, and 30 controls were enrolled. The concentration of Serum Sema7A in the AAD group was significantly higher than that in the control, AMI and PE group. Serum Sema7A was positively correlated with D-dimer. In AAD patients who underwent invasive intervention therapy, serum Sema7A levels were significantly decreased after the intervention. Serum Sema7A was an independent risk factor for the presence of AAD. The areas under the ROC curve of Sema7A and D-dimer for differential diagnosis of AAD from other chest pain disorders were 0.842 (0.776, 0.909) and 0.788 (0.714, 0.862), respectively.

CONCLUSIONS

Sema7A is highly expressed in patients with AAD. Sema7A might be a valuable biomarker for the early diagnosis of AAD and has the potential to differentiate AAD from AMI and PE.

摘要

背景

观察急性主动脉夹层（AAD）患者血清 Sema7A 水平及其对 AAD 的诊断价值。

研究设计与方法

纳入胸痛患者，包括 AAD、急性心肌梗死（AMI）或肺栓塞（PE）患者，以及无胸痛或心血管疾病的患者作为对照组。检测并比较各组患者的血清 Sema7A 和血浆 D-二聚体水平。

结果

共纳入 85 例 AAD 患者、55 例 AMI 患者、15 例 PE 患者和 30 例对照组。AAD 组血清 Sema7A 浓度明显高于对照组、AMI 组和 PE 组。血清 Sema7A 与 D-二聚体呈正相关。接受介入治疗的 AAD 患者，介入治疗后血清 Sema7A 水平明显降低。血清 Sema7A 是 AAD 发生的独立危险因素。Sema7A 和 D-二聚体鉴别 AAD 与其他胸痛疾病的 ROC 曲线下面积分别为 0.842（0.776，0.909）和 0.788（0.714，0.862）。